NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NCI E-181-2017-0-EP-13 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS EP National Stage 18792591.2 Pending
NCI E-181-2017-0-CR-11 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CR National Stage 2020-0150 Pending
NCI E-181-2017-0-CA-09 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS CA National Stage 3076339 Pending
NCI E-181-2017-0-PCT-02 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS PCT PCT PCT/US2018/051641 Expired
NCI E-181-2017-0-IN-15 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS IN National Stage 202047011647 Pending
NCI E-181-2017-0-KR-17 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS KR National Stage 2020-7011112 Pending
NCI E-181-2017-0-SG-20 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS SG National Stage 11202002425P Pending
NCI E-181-2017-0-BR-08 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS BR National Stage BR112020005469-0 Pending
NCI E-181-2017-0-AU-07 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS AU National Stage 2018335274 Pending
NCI E-181-2017-0-MX-18 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS MX National Stage MX/a/2020/003117 Pending
NCI E-231-2017-0-PCT-02 IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN PCT PCT PCT/US2018/051418 Expired
NCI E-181-2018-1-US-01 OXYNITIDINE DERIVATIVES USEFUL AS INHIBITORS OF TOPOISOMERASE IB (Top1) AND TYROSYL-DNA PHOSPHODIESTERASE 1(Tdp1) US 62/732,885 Abandoned
NCI E-237-2017-1-AU-03 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION AU National Stage 2018342245 Issued
NCI E-237-2017-2-CN-05 T CELL RECEPTORS RECOGNIZING MUTATED P53 CN National Stage 201880074539.8 Issued
NCI E-237-2017-2-EA-07 T CELL RECEPTORS RECOGNIZING MUTATED P53 EA National Stage 202090757 Issued
NCI E-237-2017-2-RU-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 RU EA 202090757 Issued
NCI E-237-2017-1-JP-08 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION JP National Stage 2020-517553 Issued
NCI E-237-2017-2-JP-11 T CELL RECEPTORS RECOGNIZING MUTATED P53 JP National Stage 2020-517556 Issued
NCI E-130-2016-0-US-04 ANTI-pY1235-MET IMMUNOLOGICAL BINDING REAGENT US National Stage 16/085,999 1134-02-19 Issued PDF
NCI E-130-2016-0-GB-07 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT GB EP 17714118.1 Issued
NCI E-130-2016-0-EP-03 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT EP National Stage 17714118.1 Issued
NCI E-130-2016-0-DE-05 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT DE EP 17714118.1 Issued
NCI E-130-2016-0-FR-06 ANTI-PY1235-MET IMMUNOLOGICAL BINDING REAGENT FR EP 17714118.1 Issued
NIAID E-242-2014-0-US-04 A Monoclonal Antibody Against The N-terminal Portion Of The Circumsporozoite Protein Of Plasmodium Falciparum US CON 16/133,143 10501534 Issued PDF
NINDS E-143-2002-1-US-78 METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS US CON 16/132,852 Abandoned
NCI E-237-2017-1-EP-06 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION EP National Stage 18782605.2 Pending
NCI E-237-2017-2-EP-08 T CELL RECEPTORS RECOGNIZING MUTATED P53 EP National Stage 18780006.5 Pending
NCI E-237-2017-2-KR-12 T CELL RECEPTORS RECOGNIZING MUTATED P53 KR National Stage 2020-7012344 Pending
NCI E-237-2017-2-SG-15 T CELL RECEPTORS RECOGNIZING MUTATED P53 SG National Stage 11202002636P Pending
NCI E-237-2017-1-KR-09 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION KR National Stage 2020-7012343 Pending
NCI E-237-2017-1-SG-10 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION SG National Stage 11202002635R Abandoned
NCI E-237-2017-2-BR-03 T CELL RECEPTORS RECOGNIZING MUTATED P53 BR National Stage BR112020006012-7 Pending
NCI E-237-2017-2-AU-02 T CELL RECEPTORS RECOGNIZING MUTATED P53 AU National Stage 2018342246 Pending
NCATS E-018-2016-0-US-15 Antifungal Compound Process US DIV 16/132,973 Abandoned
NCI E-237-2017-1-PCT-02 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION PCT PCT PCT/US2018/051280 Expired
NCI E-237-2017-2-PCT-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 PCT PCT COMB PCT/US2018/051285 Expired
NCI E-237-2017-2-IL-09 T CELL RECEPTORS RECOGNIZING MUTATED P53 IL National Stage 273515 Pending
NCI E-237-2017-1-IL-07 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION IL National Stage 273516 Pending
NCI E-237-2017-2-IN-10 T CELL RECEPTORS RECOGNIZING MUTATED P53 IN National Stage 202047013911 Pending
NCI E-205-2018-0-US-01 BICISTRONIC CHIMERIC ANTIGEN RECEPTORS TARGETING CD19 AND CD20 AND THEIR USES US 62/732,263 Abandoned
NCI E-237-2017-2-MX-13 T CELL RECEPTORS RECOGNIZING MUTATED P53 MX National Stage MX/a/2020/003504 Pending
NCI E-237-2017-1-CN-05 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION CN National Stage 201880063656.4 Pending
NCI E-237-2017-1-CA-04 METHODS OF ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR A P53 CANCER-SPECIFIC MUTATION CA National Stage 3080274 Pending
NCI E-237-2017-2-CA-04 T CELL RECEPTORS RECOGNIZING MUTATED P53 CA National Stage 3077024 Pending
NCI E-237-2017-2-CR-06 T CELL RECEPTORS RECOGNIZING MUTATED P53 CR National Stage 2020-0170 Pending
NCI E-013-2018-0-EP-07 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development EP National Stage 18856142.7 Issued
NCI E-013-2018-0-US-03 Compositions and Methods For Treating Cancer With Anti-CD19 Immunotherapy US ORD 16/132,064 10501539 Issued PDF
NCI E-013-2018-0-PCT-02 COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ANTI-CD19 IMMUNOTHERAPY PCT PCT PCT/US2018/051167 Expired
NCI E-013-2018-0-CN-06 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development CN National Stage 201880074006.X Pending
NCI E-013-2018-0-CA-05 Fully Human Antibody Targeting Human CD19 For Cancer Therapeutic Development CA National Stage 3075915 Pending